sidered that the HBP was controlled(C) when the average daytime of sistolic BP(SBP) and diastolic(DBP) were Ͻ135-85, partially controlled(PC) when they were between 136/139 and/or 86/89 and not controlled(NC) when the BP was Ͼ140-90. We analyzed the percentage of BP control in each group, the number of drugs used, and what drugs and combination brought about a better control and if there were differences according to age and gender. The results were analyzed using the Students's t, Mann-Whitney and Kruskal-Wallis tests. A level of p Ͻ.05 were considered statistically significant. CBP:300 P (62%), average(%): 122,8Ϯ8.10 / 74.6Ϯ7.45; NCBP:118 P (24, 5%), %BP:145Ϯ9.26 / 88.7Ϯ 10.3; PCBP:64 P(13,3%), %BP:134Ϯ4.71 / 82.9Ϯ 6.42. Women showed a 67% of HBP control and men a 55.5%. With monotherapy 141 P achieved BPC(61%), with two drugs 135 P(62,2%) and with three or more drugs, 24 P(70.6%). ␤-bloquers(␤B) administered as monotherapy showed the greater percentage of BP control: 83.7%, followed by angiotensin II receptor antagonist(ARA). The combination therapy (two drugs) which had the greater BPC was similar among the ␤BϩARA and ACEIϩ␤B, with a 78.6%, followed by the ACEIϩCA, 65.1%. The fixed low-dose combination more successful was ACEIϩD, 55.5%. We demostrated a good control of HBP with very little differences between the use of one and three drugs. ␤B showed the greater control as monotherapy and combined with ARA and ACEI. Among the fixed low-dose combination, ACEIϩD was the most success. The women controlled better the HBP than the men and had lower DBP values in all groups. The men showed lower SBP values in the NC and PC groups. These results support the great success of the HBP control in the specialized center. Ambulatory Blood Pressure Monitoring (ABPM) is an ideal tool for intervention studies due to its better reproducibility than the clinic measurements. Numerous studies have shown an absence of normal nocturnal decrease of blood pressure in type 1 and type 2 diabetes mellitus. This blunted nocturnal decrease has been described in transitional phase from Normoalbuminuria (NAU) to microalbuminuria (MAU) and clinical proteinuria (CP).
P-428 24 HOUR AMBULATORY BLOOD PRESSURE MONITORING IN DIABETIC HYPERTENSIVE PATIENTS WITH VARYING DEGREES OF ALBUMINURIA
Ambulatory Blood Pressure Monitoring (ABPM) is an ideal tool for intervention studies due to its better reproducibility than the clinic measurements. Numerous studies have shown an absence of normal nocturnal decrease of blood pressure in type 1 and type 2 diabetes mellitus. This blunted nocturnal decrease has been described in transitional phase from Normoalbuminuria (NAU) to microalbuminuria (MAU) and clinical proteinuria (CP).
The objective of the study was to determine the effect of albuminuria on ambulatory blood pressures using classification of the ad hoc panel of the American Society of Hypertension (Flores et al, AJH 2000) . Chart analysis of 500 patients revealed 88 eligible diabetic and hypertensive patients following up at the Rush University Hypertension clinic. Blood pressues, HbA1c, renal functions, and proteinuria was recorded. 24 hour ABPMs were done using portable recorders. The automated information was downloaded and examined. Data was analyzed in 30 normoalbuminuric (NAU), 31 microalbuminuric (MAU), and 27 clinically proteinuric (CP) patients.
The day time average SBP was significantly increased in clinically proteinuric group. However, the average day time DBP was not significantly different between the groups. In contrast the night time SBP and DBP was significantly increased in the clinically proteinuric group. Recommendations of ASH were useful in detecting early abnormalities and gradations in blood pressure with increasing albuminuria. Clinically it helps to initiate early antihypertensive treatment even before onset of albuminuria. Erectile Dysfunction (ED), also known as Impotence, is one type of very common medical condition affecting sexual health. Besides age there are other risk factors for ED, which include hypertension, diabetes, coronary artery disease, hyperlipidemia, smoking and depression. We proposed to test the efficacy of viagra in patients with hypertension and other comorbid conditions. As is well known that uncontrolled blood pressure can itself lead to erectile dysfunction, hence, only hypertensive patients with well controlled BP were selected. A total of 580 charts were reviewed, 173 (30%) were found to have complains of erectile dysfunction. Complaints of ED were predominantly a result of direct questioning by the physician, seldom it was self reported by the patients. Sexual Health Inventory for Men (SHIM) forms were completed by all male patients. Physicians entered the SHIM scores into the existing Dynamic Medical Record Database. After an adequate trial with Viagra, the SHIM scores were again recorded in the database.
To compare the efficacy of viagra in patients with hypertension alone and in those with hypertension and other co-morbid conditions a comparison of pre and post SHIM scores was undertaken, a wilcox and signed-rank test was also performed. These tests revealed a PϽ0.001 for the efficacy of viagra in Patients with hypertension and coexisting comorbid conditions when compared to PϽ0.72 for patients with hypertension alone.
The above study shows beyond doubt that viagra is highly efficacious 192A AJH-May 2003-VOL. 16, NO. 5 , PART 2 POSTERS: Clinical Trials in patients with hypertension and in those with hypertension and other co-morbid conditions like diabetes, hyperlipidemia and vascular disease etc. However, the effect is markedly pronounced in patients with hypertension with comorbid conditions. Sexual health is an important part of an individual's overall physical and emotional well being. The above observations affecting millions will help physicians achieve this difficult aspect in patient care. Arthritis and Hypertension are common co-morbid conditions affecting elderly adults. Hypertensive patients on antihypertensive medications can have destabilization of BP control and other cardiorenal events with the use of NSAIDs. The potential for similar interactions with COX-2 inhibitors is being explored. This study involves the effects of selective COX-2 inhibitor (Celecoxib) on renal functions and blood pressure. This is a 12 week, randomized, crossover trial in elderly African-Americans and Hispanic patients with osteoarthritis. Patients were randomized to 200 mg once daily of celecoxib or 75 mg bid of Diclofenac. Primary end point was change in Sytolic/ diastolic BP. Other end points included GFRs, microalbuminuria, pain relief and development of edema. One month of drug treatment was followed by 2 weeks of washout period. BP changes were assessed with 24 hour ABPMs. GFR was estimated by Iohexol (I-125) clearance. Microalbuminuria was measured using spot albumin:creatinine ratios. The effects of celecoxib and diclofenac are as shown in the table below:
Because of the dosing issues and early a.m cardiovascular risk ABPM data was dissected into 3 time frames: 24 hour as shown in the table above and 2 other time frames: 4-10 pm, in order to take into consideration the pharmacodynamics of the single dose administration of celebrex and the 6-10 am the following day to account for any adverse effects these two drugs might have that would increase the CV risk for stroke. The 4-10 pm ABPM data revealed celecoxib to be worser than NSAID on BP control (PϽ0.05). The 6-10 am ABP data for the following day revealed celecoxib to be as bad as NSAIDs for BP control.
The potential of COX-2 inhibitors on BP and renal effects are being exhaustively explored and new data is emerging. The above study reveals the deleterious effects of celecoxib on BP control and the attendant CV risk it might impose by increasing the early am BP by a few mm Hg thereby predisposing patients to fatal or morbid CV events.
Key Words: COX-2 inhibitors/NSAIDs, Hypertension, Kidney Function
P-431 DESIGN OF THE ACCOMPLISH (AVOIDING CARDIOVASCULAR EVENTS THROUGH COMBINATION THERAPY IN PATIENTS LIVING WITH SYSTOLIC HYPERTENSION) TRIAL
Large-scale hypertension studies have indicated the benefits of achieving substantial reductions in blood pressure (BP); however, most patients require combinations of antihypertensive agents to achieve target BP. ACCOMPLISH (Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension)-a prospective, randomized, multicenter, double-blind, active-controlled trial-will evaluate the efficacy of initial therapy with benazepril/amlodipine fixed-dose combination therapy compared with that of the combination of benazepril and hydrochlorothiazide (HCTZ) on the incidence of cardiovascular (CV) morbidity and mortality in high-risk, hypertensive patients. AC-COMPLISH is the first major trial to start with combination antihypertensive therapy. The study will enroll Ͼ12,000 patients in more than 650 centers in the US and Europe. Men and women Ն60 years of age with a systolic BP Ն160 mm Hg and a diastolic BP Յ115 mm Hg (in previously untreated patients) are eligible for the trial if they have at least 1 CV disease (prior myocardial infarction, stroke or current diabetes), or evidence of impairment in at least 2 target organs. Target BP will be Ͻ140/90 mm Hg, however, a more aggressive target (eg, Ͻ130/85 mm Hg) may be utilized at the investigator discretion, such as in patients with diabetes. Patients will be randomly assigned to either amlodipine/benazepril 5/20 mg qd or benazepril ϩ HCTZ 20/12.5 mg qd for 1 month. At 1 month, doses will be force titrated to amlodipine/benazepril 5/40 mg qd or benazepril ϩ HCTZ 40/12.5 mg qd. If target BP is not achieved at 2 months, doses will be uptitrated to amlodipine/benazepril 10/40 mg qd or benazepril ϩ HCTZ 40/25 mg qd. Specific add-on therapies (beta blockers, alpha blockers, or loop diuretics) are permitted should target BP not be achieved by 3 months. The primary endpoint of the trial will be time to first composite CV morbidity/mortality event (morbidity defined as nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure, unstable angina, or revascularization 
